SERMs: evolutionary chemistry, revolutionary biology

Area of Science:

• Endocrinology
• Pharmacology
• Medicinal Chemistry

Background:

• Estrogens modulate sexual physiology and impact non-traditional tissues like bone, cardiovascular system, and CNS.
• Estrogen therapy in postmenopausal women faces concerns regarding uterine and breast tissue proliferation.
• Hormone replacement therapy (HRT) with progestins mitigates uterine effects but not breast effects, and causes compliance issues.

Purpose of the Study:

• To review the evolution of selective estrogen receptor modulators (SERMs) beyond tamoxifen and raloxifene.
• To highlight the limitations of current SERMs, such as raloxifene, in addressing menopausal symptoms and cardiovascular markers.
• To discuss the ongoing efforts in medicinal chemistry to develop improved SERMs with enhanced therapeutic profiles.

Main Methods:

• Review of scientific literature on estrogen receptors and SERM development.
• Analysis of the mechanisms of estrogen action through nuclear receptor pathways.
• Examination of clinical data and side effect profiles of existing SERMs.

Main Results:

• Discovery of a second estrogen receptor (ERbeta) offers new therapeutic avenues.
• Raloxifene, while approved for osteoporosis, has limitations in treating hot flashes, urogenital complaints, and HDL levels, and increases venous thromboembolism risk.
• Current SERMs represent an evolutionary step, but the ideal SERM with maximized benefits and minimized risks is yet to be realized.

Conclusions:

• The development of SERMs has progressed significantly, offering alternatives to traditional HRT.
• There is a continuous need for medicinal chemistry innovation to create superior SERMs.
• The ultimate goal is to achieve a SERM that optimizes estrogen's beneficial effects while mitigating its adverse effects in postmenopausal women.